High Cost Drugs - FOI Response Register

1. For the 4 months from January to April 2025, how many unique patients received the following intra-vitreal treatments for any eye condition:

• Aflibercept:

85 patients

• Bevacizumab:

 None

• Brolucizumab:

 None

• Dexamethasone:

 None

• Faricimab:

 9 patients

• Ranibizumab:

<5 patients

Where we have given a <5 answer, this is because NHS Shetland considers that providing more specific information carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.